Amy Curley
Vice President, Discovery Biology Sepia Therapeutics
Seminars
Wednesday 16th September 2026
Exploring Epigenetic Editing Approaches to Target Fibrotic Drivers, Enable Precision Modulation & Expand Next-Generation MASH Therapeutic Strategies
12:30 pm
- Inhibiting the pleiotropic fibrotic processes driving MASH via nonpermanent epigenetic editing (‘epi-editing’); enabling precision therapeutic intervention and expanding next-generation MASH development strategies
- Leveraging epi-editing to develop innovative and differentiated next-generation therapeutic strategies to treat steatosis and fibrosis in MASH
- Expanding pipeline opportunities by tackling undruggable targets through epi-editing gene activation or repression
